RecruitingPhase 1NCT06313593
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
Sponsor
Incyte Corporation
Enrollment
186 participants
Start Date
Aug 8, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- Age ≥ 18 years
- MF:
- Intermediate-1 or higher risk PMF, post-PV MF, or post-ET MF with evidence of minimum burden of disease based on splenomegaly, and for the monotherapy cohort, participants must have been previously treated with at least 1 JAK inhibitor for ≥ 12 weeks and resistant, refractory, intolerant to, or have lost response to JAK inhibitor treatment.
- For the MF SubOpt R cohort: Therapeutic regimen prior to enrollment as defined in the protocol and unlikely to benefit from further monotherapy in the opinion of the investigator.
- PV: Confirmed diagnosis of PV and previously treated with at least 1 prior standard cytoreductive therapy and are resistant, refractory, intolerant to, or have lost response to treatment.
- ET: Confirmed diagnosis of high-risk ET as defined in the protocol and previously treated with at least 1 prior standard cytoreductive therapy and are resistant, refractory, intolerant to, or have lost response to treatment.
- Life expectancy > 6 months.
- Willingness to undergo a pretreatment and regular on-study bone marrow biopsies and aspirations (as appropriate to disease).
- Existing documentation of JAK2V617F mutation from a qualified local laboratory.
Exclusion Criteria9
- Presence of a hematological malignancy requiring treatment, other than PMF, post-PV MF, post-ET MF, PV, or ET.
- Prior history of major bleeding or thrombosis within the 3 months prior to study enrollment.
- Participants with abnormal hematologic, hepatic, or renal function based on laboratory evaluation.
- Has undergone prior allogenic or autologous stem-cell transplantation or allogenic stem-cell transplantation is planned
- Active invasive malignancy.
- Significant concurrent, uncontrolled medical condition.
- Acute or chronic HBV, active HCV or known HIV.
- Any prior MPN-directed therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
- Participants undergoing treatment with G-CSF or GM-CSF, romiplostim, or eltrombopag at any time within 4 weeks before the first dose of study treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGINCB160058
Oral; Tablet
DRUGStandard disease-directed therapy
A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.
Locations(31)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06313593
Related Trials
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT0700811826 locations
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT0593635929 locations
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT0744169445 locations
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT0603400213 locations
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
NCT062919871 location